Effect of Calcitonin on Healing Duration, Function and Pain Relief in Patients with Maxillofacial Fractures. A pilot study

Javad Yazdani, Farzin Ahmadpour

Abstract


Introduction: Calcitonin is a polypeptide hormone regulating the metabolism calcium in the body. Many studies showed that calcitonin had analgesic effect on several painful circumstances. The aim of this study was to determine the effects of intranasal calcitonin during the immediate postoperative period on postoperative pain in patients undergoing maxillofacial fracture surgery. Materials and Methods: In this clinical trial which was conducted in April 2019 in Imam Reza Hospital of Tabriz, 16 patients with maxillofacial fracture were divided randomly into two groups. The intervention group was given 200UI of intranasal calcitonin and the control group received nasal spray of NaCl. The severity of pain was then evaluated daily for up to seven days after the operation, with the severity of: no pain (0) to the most severe pain (10) using visual analog scale for pain. The daily dose of analgesic was also measured. The patients were allowed to request 250 mg of injectable acetaminophen each day up to a maximum daily dose of 4 g (maximum permissible dose) in the event of pain. Results: The results show that the pain intensity between two groups was not significantly different. However in the seventh day the total acetaminophen consumption was significantly lower in the intervention group. Conclusion: calcitonin may be a useful medication to help to control the post operative pain by reducing the required dose of routine painkillers.

Keywords


Calcitonin, Intranasal, Maxillofacial Fracture

Full Text:

PDF

References


Mandal D, Das A, Chhaule S, Halder PS, Paul J, RoyBasunia S, et al. The effect of dexmedetomidine added to preemptive (2% lignocaine with adrenaline) infiltration on intraoperative hemodynamics and postoperative pain after ambulatory maxillofacial surgeries under general anesthesia. Anesth Essays Res. 2016;10(2):324-31. Epub 2016/05/24.

Lyritis GP, Trovas G. Analgesic effects of calcitonin. Bone. 2002;30(5 Suppl):71S-4S. Epub 2002/05/15.

Braga PC. Calcitonin and its antinociceptive activity: animal and human investigations 1975-1992. Agents Actions. 1994;41(3-4):121-31. Epub 1994/05/01.

Yeh CB, Weng SJ, Chang KW, Chan JY, Huang SM, Chu TH, et al. Calcitonin alleviates hyperalgesia in osteoporotic rats by modulating serotonin transporter activity. Osteoporos Int. 2016;27(11):3355-64. Epub 2016/06/05.

Chesnut CH, 3rd, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int. 2008;19(4):479-91. Epub 2007/12/12.

Viana R, Payne MW. Use of calcitonin in recalcitrant phantom limb pain complicated by heterotopic ossification. Pain Res Manag. 2015;20(5):229-33. Epub 2015/08/21.

Appelboom T. Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions. Bone. 2002;30(5 Suppl):84S-6S. Epub 2002/05/15.

Gennari C, Bocchi L, Orso CA, Francini G, Civitelli R, Maioli E. The Analgesic Effect of Calcitonin in Active Paget's Disease of Bone and in Metastatic Bone Disease. Orthopedics. 1984;7(9):1449-52. Epub 1984/09/01.

Sarveravan P, Astaneh B, Shokrpour N. Adherence to the CONSORT Statement in the Reporting of Randomized Controlled Trials on Pharmacological Interventions Published in Iranian Medical Journals. Iran J Med Sci. 2017;42(6):532-43. Epub 2017/12/01.




DOI: http://dx.doi.org/10.7575/aiac.abcmed.v.7n.4p.1

Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

2013-2020 (CC-BY) Australian International Academic Centre PTY.LTD.

Advances in Bioscience and Clinical Medicine